Research

Large-scale HIV vaccine trials have finally begun

On the pages of our portal, we have repeatedlythey told you that scientists are creating different types of vaccines for one of the worst diseases on our planet - the human immunodeficiency virus (HIV). But then it was only development or small laboratory tests. Now, doctors are ready to test a new HIV vaccine on humans. And the tests are not limited to a small group of people. The vaccine will be tested on a huge number of volunteers on three continents at once.

How HIV vaccine works

New medicine is called "mosaic"a vaccine (‘Mosaic’ HIV vaccine) and the essence of how it is structured is the name. It includes the genetic material of several strains of human immunodeficiency virus. The vaccine itself is collected, roughly speaking, “bit by bit”, taking part of each virus strain and connecting them together. That is, as a result, the “assembled” vaccine consists of individual parts of viruses, like a picture assembled from pieces of a mosaic (you can also try to draw an analogy with puzzle pieces, but this does not change the essence).

See also: How with the help of genetic engineering managed to defeat HIV.

According to Nature’s editors,Vaccines are inactivated by the genome of the common cold virus, in which three synthetic HIV genes are inserted. They were created on the basis of strains identified in different regions of the globe. According to scientists, the "mosaic" vaccine has a rather long-lasting effect and is able to protect against more types of HIV.

When will they start testing the HIV vaccine?

The clinical trial phase of the new vaccine will beginalready in September 2019. The tests will take 3800 volunteers from 8 European countries, as well as from several countries in North and South America. The study will involve mostly transgender, homosexual and bisexual men, since according to statistics, it is these population groups that are most vulnerable to HIV.

Vaccination involves the administration of four doses.vaccines, the last two of which are supplemented with synthetic proteins that enhance the production of antibodies against human immunodeficiency virus. Vaccine administration will occur within one year. In this case, half the subjects will receive 4 doses of this vaccine, and the other half - a placebo. Naturally, participants in the experience will not know what they are getting.

The previous test stages confirmed thatA "mosaic" vaccine causes a strong immune response to HIV, and now scientists need to understand whether it provides long-term protection against the virus. Now scientists are optimistic about the project and hope that the vaccine will prove its effectiveness. However, part of the scientific community believes that HIV can quickly mutate and acquire resistance to a “mosaic” vaccine.

You can discuss this and other news in our chat in Telegrams.